Changes in Hong Kong stocks | Danuo Pharmaceutical-B (06872) rose nearly 3% and recently signed an exclusive commercial cooperation agreement supplementary agreement with Yuanda Life Sciences

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Danuo Pharmaceutical-B (06872) rose nearly 3%. As of press release, it had risen 2.43% to HK$69.5, with a turnover of HK$3,577,900.

According to the news, Danno Pharmaceutical-B announced that the company has been actively promoting the approval process and corresponding commercialization preparations for the first indication of rifonidazole in China. In order to cooperate with the relevant review process, ensure that the cooperation arrangement is consistent with the expected commercialization schedule of rifonidazole, and further strengthen the long-term cooperative relationship between the company and Yuanda Life Sciences, the board of directors is pleased to announce that on November 12, 2026, the company and Yuanda Life Science signed a supplementary agreement to the cooperation agreement.

Based on this, the two parties agreed to extend the relevant period under the cooperation agreement relating to Yuanda Life Sciences's right to unilaterally terminate the cooperation agreement through a written notice due to the company's failure to obtain permission to market the first indication of rifonidazole in China before the specified date, from December 31, 2026 to July 31, 2027.